Oral paclitaxel plus radiation for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an oral chemotherapy drug (paclitaxel) and radiation therapy for people with advanced esophageal cancer that cannot be removed by surgery. It may be an option if you are 70 or older or cannot tolerate IV chemotherapy and have trouble swallowing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma that has spread to nearby lymph nodes but not to distant organs.
- You are 70 years or older, or you cannot take IV chemotherapy because of other health problems and have severe trouble swallowing.
- You have not had chemotherapy or radiation for esophageal cancer before.
- Your cancer cannot be removed by surgery.
- Your blood, kidney, and liver function are within acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, chemotherapy (cisplatin and paclitaxel), and an immunotherapy drug called camrelizumab for patients with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if adding immunotherapy improves outcomes compared to standard treatment alone.
This trial tests if giving chemotherapy and radiation before surgery, followed by immunotherapy, can improve outcomes for people with a specific type of esophageal cancer that can be surgically removed.
This study compares a planned radiation approach given at the same time as other treatment for older adults with esophageal squamous cell carcinoma. It may help find a safer and more effective radiation schedule for people who are fit enough for treatment.
This trial tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (cadonilimab) given before surgery for advanced esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests combining the immunotherapy drug carrelizumab with standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this combination can help shrink or control the tumor.
This trial studies whether a combination of chemotherapy and radiation can help people with advanced esophageal cancer who cannot have curative treatment. It focuses on people who are having swallowing trouble and may be able to start treatment soon.
Hear when a new Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.